je.st
news
Alnylam Provides Key 2014 Goals For RNAi Therapeutics Pipeline
2014-02-05 07:22:08| drugdiscoveryonline News Articles
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, recently announced its key “Alnylam 5x15” pipeline goals. The company also announced today that it now expects to exceed its original “Alnylam 5x15” guidance from 2011, where Alnylam had guided to have five genetic medicine programs in the clinic by the end of 2015
Tags: key
goals
pipeline
therapeutics
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||